MediaMedic

ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies

By Peter W. PENG 2025.12.18

At the 67th Annual Meeting of the American Society of Hematology (ASH), Professor Lu Peihua and Professor Zhang Xian from Lu Daopei Hospital presented a large-scale clinical study of a…

ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification

By Mourabit Halima 2025.12.17

Immune thrombocytopenia (ITP) is an immune-mediated thrombocytopenic disorder that can lead to severe bleeding and markedly impair quality of life. At the 67th Annual Meeting of the American Society of…

ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

By Mourabit Halima 2025.12.17

On December 6 (local time), a highly anticipated special session on the ASH Clinical Practice Guidelines on Myelofibrosis was successfully held during the American Society of Hematology (ASH) Annual Meeting.…

ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

By Peng Longmei 2025.12.17

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international…

ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

By Mourabit Halima 2025.12.17

At this year’s Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang Haiwen from the First Affiliated Hospital of Soochow University reported multiple important…

ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

By Peter W. PENG 2025.12.16

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together the latest global research and clinical advances…

ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

By Peng Longmei 2025.12.16

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the largest and most influential international congress…

ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

By Mourabit Halima 2025.12.16

Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by marked heterogeneity and complex prognosis. While treatment of intermediate- and high-risk disease remains challenging, there is also considerable…

ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL

By Mourabit Halima 2025.12.15

To promote innovation in China’s cell and immunotherapy fields, deepen scientific exchange, and accelerate translation through global collaboration, the 2025 International Cell & Immunotherapy Conference (CTI 2025) was held on…

TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer

By Mourabit Halima 2025.12.15

At the recently concluded European Society for Medical Oncology Asia Congress (ESMO Asia), participating experts shared and reviewed the latest advances in numerous breast cancer clinical studies. Oncology Frontier has…

CRC Cooperation Between Italy and China: Insights from Dr. Federico Maria Mongardini

From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

ESMO BC Voices From China | Real-World Study From Yunnan Cancer Hospital Identifies High-Risk Features Associated With Early Rapid Progression After First-Line CDK4/6 Inhibitor Therapy in HR+/HER2− Advanced Breast Cancer

Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

ESMO BC 2026 | A Potential New First-Line “China Regimen” for Advanced TNBC: Professor Jian Zhang Reports Phase II Study of a Novel TROP2 ADC Combined With a PD-L1/VEGF-A Bispecific Antibody

ESMO BC Voices From China | Professor Nanlin Li: Neratinib-Based Combination Therapy Opens a New Path Forward for T-DXd-Resistant HR+/HER2+ Advanced Breast Cancer

47Sino-French Breast Reconstruction Congress | Professor Yongsheng Wang: From Precision Decision-Making to Standardized Training—Advancing Individualized Axillary Management

Sino-French Breast Reconstruction Congress | Professor Jiong Wu: Building a Replicable and Scalable “FUSCC Model” to Bring High-Quality Breast Reconstruction to More Patients

Professor Guosheng Ren & Professor Nicolas Leymarie: Rebuilding Lives, Advancing Together—Reflections and Future Perspectives on Sino-French Breast Reconstruction Collaboration | Sino-French Breast Reconstruction Congress

2026 HOT Conference | Professor Tengfei Chao: Precision Treatment Strategies After Progression on CDK4/6 Inhibitor Plus Endocrine Therapy

CRC Cooperation Between Italy and China: Insights from Dr. Federico Maria Mongardini

From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies

ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification

ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL

TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer

CRC Cooperation Between Italy and China: Insights from Dr. Federico Maria Mongardini

From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

ESMO BC Voices From China | Real-World Study From Yunnan Cancer Hospital Identifies High-Risk Features Associated With Early Rapid Progression After First-Line CDK4/6 Inhibitor Therapy in HR+/HER2− Advanced Breast Cancer

Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Welcome to Mediamedic 👋
It’s nice to meet you.

Welcome to Mediamedic 👋It’s nice to meet you.

Welcome to Mediamedic 👋
It’s nice to meet you.